{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:19:11Z","timestamp":1771953551043,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1053\/j.seminoncol.2005.04.004","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"24-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S4","title":["Experience With Docetaxel in the Treatment of Gastric Cancer"],"prefix":"10.1053","volume":"32","author":[{"given":"Philip A.","family":"Philip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2005.04.004_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10120-002-0203-6","article-title":"The epidemiology of gastric cancer","volume":"5","author":"Roder","year":"2002","journal-title":"Gastric Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib2","first-page":"10","article-title":"Cancer statistics, 2005","volume":"5","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib3","first-page":"292","article-title":"Pathologic and phenotypic features of gastric cancer","volume":"23","author":"Fenoglio-Preiser","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib4","first-page":"11","article-title":"The diagnosis of gastric cancer","volume":"12","author":"Kurtz","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0002-9343(98)00393-3","article-title":"Helicobacter pylori and gastric cancer","volume":"106","author":"Scheiman","year":"1999","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib6","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology - v.1.2003","DOI":"10.6004\/jnccn.2003.0010"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib7","unstructured":"National Cancer Institute. Gastric Cancer (PDQ): Treatment. Revised June 5, 2003. Available at: http:\/\/www.cancer.gov (accessed August 21, 2003)"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0959-8049(95)00500-5","article-title":"Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo","volume":"32A","author":"Tanaka","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02993858","article-title":"Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy","volume":"13","author":"Einzig","year":"1996","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00000421-200008000-00005","article-title":"Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF). A phase II trial","volume":"23","author":"Mavroudis","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bjc.1994.310","article-title":"Docetaxel (Taxotere) in advanced gastric cancer","volume":"70","author":"Sulkes","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jjco\/hyf057","article-title":"Docetaxel 75 mg\/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer","volume":"32","author":"Bang","year":"2002","journal-title":"Jpn J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib13","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/S0959-8049(99)81005-3","article-title":"Docetaxel as salvage chemotherapy in advanced gastric cancer patients (AGC)","volume":"35","author":"Giuliano","year":"1999","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"10.1053\/j.seminoncol.2005.04.004_bib14","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0959-8049(99)80957-5","article-title":"Phase II study of docetaxel (D) as salvage chemotherapy in patients with advanced gastric cancer","volume":"35","author":"Vanhoefer","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1023\/A:1008373814453","article-title":"A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer","volume":"11","author":"Graziano","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000065471","article-title":"A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil\/leucovorin and cisplatin in patients with advanced gastric cancer","volume":"63","author":"Chen","year":"2002","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib17","first-page":"171a","article-title":"Phase I study of docetaxel, cisplatin, 5-FU and leucovorin","volume":"20","author":"Mulcahy","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib18","first-page":"490","article-title":"A phase I study of docetaxel (Taxotere) and 5-FU combination chemotherapy in patients with advanced solid tumors","volume":"15","author":"Peacock","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s101200200025","article-title":"Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer","volume":"5","author":"Constenla","year":"2002","journal-title":"Gastric Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib20","first-page":"162a","article-title":"Docetaxel and 5-FU continuous infusion (DF) versus epirubicin, cisplatin and 5-FU (ECF) for advanced gastric adenocarcinoma","volume":"21","author":"Thuss-Patience","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib21","first-page":"342","article-title":"Docetaxel+5-fluorouracil+cisplatin combination chemotherapy as first-line treatment in inoperable or relapsed gastric cancer","volume":"22","author":"Do-Youn","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib22","first-page":"163a","article-title":"A phase II multicentric trial of docetaxel (Taxotere), 5-fluorouracil (5-FU) and epirubicin (EPI) in previously untreated advanced gastric cancer","volume":"21","author":"Murad","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib23","first-page":"162a","article-title":"Weekly docetaxel and continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients (pts) with cancer of the stomach and distal esophagus","volume":"20","author":"Chun","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib24","first-page":"328","article-title":"Phase I-II study of docetaxel, capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer","volume":"22","author":"Kang","year":"2003","journal-title":"Proc Am Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib25","first-page":"307","article-title":"A prospective phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer","volume":"22","author":"Yeon-Hee","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1008342013224","article-title":"Docetaxel (Taxotere)\u2014cisplatin (TC)","volume":"11","author":"Roth","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s101200200028","article-title":"Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer","volume":"5","author":"Mitachi","year":"2002","journal-title":"Gastric Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib28","first-page":"105b","article-title":"TCFW:5FUpvi in combination with weekly docetaxel and CDDP in advanced gastric cancer, a phase I-II study: The dose finding step. \u201cRete Oncologica Piemontese\u201d","volume":"21","author":"Ostellino","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib29","first-page":"165a","article-title":"Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer","volume":"20","author":"Kettner","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1008328501128","article-title":"Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer","volume":"12","author":"Ridwelski","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib31","first-page":"249","article-title":"Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-na\u00efve patients with metastatic or locally recurrent unresectable gastric carcinoma (MGC)","volume":"22","author":"Ajani","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib32","first-page":"202a","article-title":"Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors","volume":"16","author":"Couteau","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib33","first-page":"225a","article-title":"Phase I dose escalation trial of weekly docetaxel (D) plus irinotecan (I) in patients with advanced solid tumors","volume":"18","author":"Rich","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib34","first-page":"344","article-title":"Weekly docetaxel, irinotecan and cisplatin (DIP); A phase I dose and schedule finding study for advanced gastric cancer (AGC)","volume":"22","author":"Saotome","year":"2003","journal-title":"Proc Am Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib35","first-page":"328","article-title":"Phase II study of irinotecan (I) and docetaxel (D) as a second line chemotherapy for patients with previously treated advanced gastric cancer (AGC)","volume":"22","author":"Chang","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib36","first-page":"362","article-title":"Docetaxel in combination with irinotecan (CPT-11) in locally advanced or metastatic gastric cancer. A Goti Cooperative Spanish Group Study","volume":"22","author":"Enrech","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib37","first-page":"257","article-title":"Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC)","volume":"22","author":"Hawkins","year":"2003","journal-title":"Proc Am Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib38","first-page":"374","article-title":"Phase II study of CPT-11 plus docetaxel in patients with metastatic gastric cancer","volume":"22","author":"Narahara","year":"2003","journal-title":"Proc Am Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002800100317","article-title":"Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer","volume":"48","author":"Bhargava","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"issue":"suppl 4","key":"10.1053\/j.seminoncol.2005.04.004_bib40","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/S0959-8049(99)81576-7","article-title":"Biweekly docetaxel (DOC), gemcitabine (GEM), oxaliplatin (LOHP) in heavily pretreated patients with solid tumors-Preliminary results of a phase I study","volume":"35","author":"B\u00fcechele","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib41","first-page":"205a","article-title":"Biweekly docetaxel (Doc), gemcitabine (Gem), oxaliplatin (LOHP) in heavily pretreated patients with solid tumors\u2014A pilot study","volume":"18","author":"Buechele","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib42","first-page":"239a","article-title":"Unique two week schedule of docetaxel and short infusion gemcitabine for advanced solid tumors","volume":"17","author":"Davis","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib43","first-page":"204a","article-title":"Phase I study of gemcitabine (G) and docetaxel (D) in patients (pts) with advanced cancer","volume":"18","author":"Boyer","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib44","first-page":"240a","article-title":"A phase I study of the combination of docetaxel (D) and gemcitabine (G)","volume":"17","author":"Eckardt","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib45","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1081\/CNV-120018225","article-title":"A phase I study of gemcitabine and docetaxel for advanced stage solid tumors","volume":"21","author":"Poole","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib46","first-page":"226a","article-title":"Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules","volume":"18","author":"Rigas","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<180::AID-CNCR25>3.0.CO;2-Q","article-title":"A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors","volume":"88","author":"Ryan","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib48","first-page":"277a","article-title":"Docetaxel-epirubicine as second-line treatment for patients with advanced gastric cancer","volume":"18","author":"Andr\u00e9","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1054\/bjoc.2000.1631","article-title":"A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian Group for the Study of Digestive Tract Cancer","volume":"84","author":"Cascinu","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib50","first-page":"307","article-title":"A phase II study of combination chemotherapy with docetaxel, epirubicin, and cisplatin in inoperable gastric cancer","volume":"22","author":"Lee","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00130404-200205000-00013","article-title":"Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-\u03b1-s2, and filgrastim or doxorubicin\/docetaxel in patients with advanced gastric cancer with quality-of-life assessment","volume":"8","author":"Wadler","year":"2002","journal-title":"Cancer J"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib52","first-page":"254a","article-title":"Phase I trial of docetaxel (DOTAX) and topotecan hydrochloride (TOPO) in patients with advanced solid tumors","volume":"17","author":"Tkaczuk","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib53","first-page":"77b","article-title":"Phase I study of pemetrexed in combination with docetaxel in patients with advanced solid malignancies","volume":"21","author":"Mackay","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib54","unstructured":"Jatoi A, protocol chair: Phase II study of docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach or gastroesophageal junction. Protocol NCCTG-N0242. Available at: ncctg.mayo.edu"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib55","first-page":"144b","article-title":"A phase II study of docetaxel in combination with irinotecan (CPT-11) in locally advanced or metastatic gastric cancer","volume":"20","author":"Enrech","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.04.004_bib56","unstructured":"Dragnev K, protocol chair: Phase I study of docetaxel, gemcitabine, and filgrastim (G-CSF) in patients with advanced solid tumors. Protocol DMS-9933, NCI-G01-1933. Available at: www.nci_nih_gov\/clinicaltrials\/view_clinicaltrials.aspx?version=healthprofession&cdrid=68545\/"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540500148X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540500148X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:52:25Z","timestamp":1758804745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377540500148X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":56,"alternative-id":["S009377540500148X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2005.04.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience With Docetaxel in the Treatment of Gastric Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2005.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}